RNTX

REIN THERAPEUTICS, INC.

RNTX · CIK 1420565 · Annual (10-K) · Last 8 years

Financial Trends

Revenue$0M
20172024
Net Income−$63M
20172024
Operating CF−$22M
20172024
Free Cash Flow
20172024

Income Statement

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕FY 2017↕
Revenue$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Cost of Revenue————————
Gross Profit————————
R&D Expense$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
SG&A Expense————————
Operating Income$-0.1B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B
Net Income$-0.1B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B
EPS (Basic)$-3.51$-3.42$-6.02—————
EPS (Diluted)$-3.51$-3.42$-6.02—————

Balance Sheet

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕FY 2017↕
Total Assets$0.1B$0.1B$0.0B$0.0B$0.0B$0.0B$0.0B$0.1B
Current Assets$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.1B
Cash & Equivalents$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Total Liabilities$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Current Liabilities$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Stockholders' Equity$0.1B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B

Cash Flow Statement

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕FY 2017↕
Operating Cash Flow$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B—
Investing Cash Flow$0.0B$0.0B$0.0B$-0.0B$0.0B$-0.0B$0.0B—
Capital Expenditures——$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Financing Cash Flow$0.0B$0.0B$0.1B$0.1B$0.0B$0.0B$0.0B—
← Companies